Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ

Completed

Conditions studied: Breast Cancer, Lobular Carcinoma, Invasive Breast Cancer

In brief

This study is being done in order to better understand the biology of an abnormal lesion found in breast tissue called "lobular carcinoma in situ" (LCIS). We are interested in studying LCIS. The LCIS is not a cancer itself, but is a marker for an increased risk of cancer. We would like to look for LCIS in breast tissue removed during surgery from patients with cancer or at high risk for cancer. If LCIS is found, we will search for genes that are expressed (turned on or off) differently than in normal breast tissue. The identification of such genes would help us better understand the biology of LCIS, and its possible relationship to breast cancer.

Key facts

Study ID

NCT00581750

Run by

Memorial Sloan Kettering Cancer Center

People needed

550

Starts

2001-10-01

Expected to finish

2021-06-28

Last updated by the study team

2021-07-02

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• multifocal lobular carcinoma in situ treated with prophylactic mastectomy or lumpectomy
• invasive breast cancer (lobular or ductal) with coexisting lobular carcinoma in situ treated with mastectomy or lumpectomy
• biopsy proven, untreated lobular carcinoma in situ
• invasive lobular cancer with or without coexisting lobular carcinoma in situ treated with mastectomy or lumpectomy

You may not qualify if…

• no paraffin blocks available
• no residual lobular carcinoma in situ in paraffin blocks

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.